Drug details:
Molecular formula: C₁₉H₁₅BrN₄

Standard name: N-benzyl-4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine

Curated SMILES: C1=CC=C(C=C1)CNC2=NC=CC(=N2)C3=CNC4=C3C=C(C=C4)Br

Evidence for compound's anti-virulence activity:

Mycobacterium
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits and disperses biofilms.
Max phase: Preclinical (in vitro)
Publications:
Huggins WM, et al., 2018. Meridianin D Analogues Display Antibiofilm Activity against MRSA and Increase Colistin Efficacy in Gram-Negative Bacteria. ACS Med Chem Lett 9(7):702-707.
Zeiler MJ, et al., 2020. Second-Generation Meridianin Analogues Inhibit the Formation of Mycobacterium smegmatis Biofilms and Sensitize Polymyxin-Resistant Gram-Negative Bacteria to Colistin. ChemMedChem 15(17):1672-1679.
Brackett SM, et al., 2020. Meridianin D analogues possess antibiofilm activity against Mycobacterium smegmatis. RSC Med Chem 11(1):92-97.

Staphylococcus
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation and increases the potency of colistin.
Max phase: Preclinical (in vitro)
Publication:
Huggins WM, et al., 2018. Meridianin D Analogues Display Antibiofilm Activity against MRSA and Increase Colistin Efficacy in Gram-Negative Bacteria. ACS Med Chem Lett 9(7):702-707.